EXTRACRANIAL VENOUS ABNORMALITIES UPDATE
Research on venous abnormalities must continue, urge UB authors of one of neurology’s most cited papers, Buffalo, NY, February 6, 2014
University at Buffalo researchers who authored one of neurology’s most cited papers in the last three years are calling for more investigation into how venous abnormalities in the neck might be involved in central nervous system disorders and aging.
The call for additional research was expressed in a December editorial and debate article in BMC Medicine, co-authored by Robert Zivadinov, MD, PhD, professor of neurology in the UB School of Medicine and Biomedical Sciences and director of the neurology department’s Buffalo Neuroimaging Analysis Center.
MS patients did not benefit from CCSVI intervention, landmark pilot study of ‘liberation treatment’ finds, Buffalo, NY, March 15, 2013
The first controlled clinical trial to test the safety and efficacy of interventional endovascular therapy on the symptoms and progression of multiple sclerosis (MS) has found that the intervention, sometimes called the “liberation treatment,” which has attracted intense interest in the global MS community, does not improve patient outcomes. In a few cases, the treatment made symptoms worse.
University at Buffalo researchers will present their results in an “Emerging Science” poster session March 20 at the annual American Academy of Neurology meeting in San Diego. They discuss their findings in this video.
Combined Transcranial and Extracranial Venous Doppler (CTEVD) Study, Buffalo, NY, February 11, 2013
This comprehensive, blinded study included over 1,000 subjects with multiple sclerosis (MS), other related diseases and healthy individuals. Researchers use information from magnetic resonance imaging (MRI) of the brain and neck veins to test the controversial extracranial venous abnormalities theory. They also study the results of Doppler ultrasound tests that monitor the rate of blood flow to and from the brain. They investigate genetic and environmental factors that may cause MS and also review the participants’ responses to a detailed environmental questionnaire. Finally, each subject has a clinical examination by an MS Specialist from the Baird MS Center, part of the Jacobs Neurological Institute, University at Buffalo. In addition, subjects were evaluated with genetic, immunology, viral and other blood assessments and with optical coherence tomography (OCT).
The results of the first 500 subjects were presented by Dr. Robert Zivadinov and his research team at the AAN annual conference in March, 2010 and were subsequently published in Neurology in 2011. The final results of CTEVD study are under analysis and number of articles are under submission in major neurological, vascular and radiological journals.
With over 1,000 subjects BNAC’s CTEVD study is one of the largest case-control studies in the world on venous, MRI, clinical and environmental factors in MS and our researchers and technicians gained considerable experience studying extra-cranial venous system. This unique expertise is critical in the analysis of how constriction of venous blood flow relates to MS, as well associations with clinical, MRI and blood biomarkers.
Update to the study participants: CTEVD study has been concluded and the results are currently being analyzed. Subjects who participated in the CTEVD study can obtain information about their individual examinations by contacting Ellen Carl at firstname.lastname@example.org or 716-859-7080.
PREMiSe Treatment Study, Buffalo, NY, February 11, 2013
BNAC is conducting this research in collaboration with the University at Buffalo’s Department of Neurosurgery. The study is testing safety and efficacy of the balloon angioplasty in 30 multiple sclerosis (MS) participants that are followed over 12 months. The study has been locked and it will be presented at a major scientific conference in the near future. As the first IRB approved sham-controlled, double-blind, randomized clinical trial to test the safety and efficacy of the extracranial venous abnormality treatment, this study is receiving international attention from among all the medical and patient communities interested in MS.
Update to the study participants: PREMiSe study has been concluded and the results are currently being analyzed. Subjects who participated in the PREMiSe study can obtain information about their individual examinations by contacting Ellen Carl at email@example.com or 716-859-7080.
Before Canadian Senate, Zivadinov Urges Caution for CCSVI Treatment, Ottawa, Canada, November 1, 2012
Dr. Zivadinov testified recently in Canadian Senate on the current research status of the CCSVI. To view this testimony click here.
Remarkable Similarity in Risk Factors for MS and CCSVI, Buffalo, NY – November 30, 2011
Dr. Zivadinov discusses risk factors for CCSVI. To view this video click here.
Patient Education Day Program, Buffalo, May 7, 2011
Drs. Robert Zivadinov, Bianca Weinstock-Guttman, and Adnan H. Siddiqui discussed on May 7, 2011 at University of Buffalo Center for Tomorrow about major extracranial venous abnormality studies they are conducting, including a 1,000-subject extracranial venous abnormality Prevalence Study and a Treatment Study in collaboration with the University at Buffalo Department of Neurosurgery. To view the presentations, please click here.
CCSVI in multiple sclerosis, a clinical context report. MedPage Today, April 07, 2012
Dr. Zivadinov participated in this extracranial venous abnormality CME program. To view this program click here.
National Multiple Sclerosis Society Web forum, Toronto, Canada, April 14, 2010
We are grateful to the National Multiple Sclerosis Society for hosting the April 14, 2010 Web forum, “CCSVI and what it could mean to people living with MS.”
To view this Web forum, featuring Dr. Paolo Zamboni, Dr. Robert Zivadinov, Dr. Andrew Common, and Dr. Aaron Miller, click here.